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Objective: Headache is the most common type of pain reported by people with schizophrenia.  
This study aimed to establish prevalence, characteristics and management of these headache.  
Method: One-hundred participants with schizophrenia/schizoaffective disorder completed a 
reliable and valid headache questionnaire. Two clinicians independently classified each 
headache as migraine (MH), tension-type (TTH), cervicogenic (CGH) or other (OH).   
Results: The twelve-month prevalence of headache (57%) was higher than the general 
population (46%) with no evidence of a relationship between psychiatric clinical characteristics 
and presence of headache. Prevalence of CGH (5%) and MH (18%) was comparable to the 
general population. TTH (16%) had a lower prevalence and 19% of participant’s experienced 
OH. No-one with MH was prescribed migraine specific medication, no-one with CGH and 
TTH received best-practice treatment   
Conclusion: Headache is a common complaint in people with schizophrenia/schizoaffective 
disorder with most fitting recognised diagnostic criteria for which effective interventions are 
available. No-one in this sample was receiving best-practice care for their headache. 
  
 Despite evidence that people with schizophrenia demonstrate blunted responses to 
nociception1-3, persistent pain is a common comorbidity4. Headache is the most common pain 
problem reported, with 12 month prevalence of around 50%5-7. Successful management of 
headache requires understanding of the mechanisms underpinning the headache experience. 
To facilitate this process, the International Headache Society has published the International 
Classification of Headache Disorders (ICHD) describing the important clinical features 
differentiating headache disorders. To our knowledge there has been no attempt to 
characterize headache types experienced by people with schizophrenia and schizoaffective 
disorder and map if care provided is appropriate. The purpose of this research was to 
determine prevalence, characteristics and management of common headache types 
experienced by people with schizophrenia/schizoaffective disorder. This information may 
help identify whether changes could be implemented to better address this manageable 
physical co-morbidity amongst this population.  
1.0 Methods 
1.1 Ethic Statement. All participants gave written informed consent. Ethical approval 
was provided through the institutional Human Research Ethics Committee. All procedures 
conformed to the Declaration of Helsinki. 
1.2 Study participants. One hundred adult participants with a medical diagnosis, made 
by their treating psychiatrist, of schizophrenia/schizoaffective disorder were recruited from a 
Metropolitan Mental Health service outpatient depot clinic and open wards between July-
November 2013. People attended the depot clinic for medication on a regular basis and 
provided a platform to recruit community/outpatient participants. People were excluded if in 
a locked ward as they did not meet selection criteria due to the acuity of their illness being 
either cognitively impaired, in a critical phase of recovery which may have been destabilised 
by participation in the interview process. Any person deemed by their case manager to pose a 
safety risk to the interviewer was excluded.   
Procedure. A previously validated headache questionnaire was identified8 and on advice 
from two independent mental health practitioners the word ‘aura’ associated with MH was 
replaced by the word ‘symptoms’. An algorithm was developed using ICHD criteria to 
classify headache into either Cervicogenic (CGH), Tension Type (TTH) or Migraine (MH) as 
well as Other Headache type (OH) when characteristics did not allow clear classification. 
Pilot testing on a non-psychiatric headache population demonstrated excellent agreement 
between raters when using the questionnaire and algorithm to classify headache type 
(weighted-κ=0.83, 95% CI 0.65-1.00).  
Potential participants were identified, approached by one of the researchers (JC) and given 
detailed information regarding the project. Willing participants signed a consent form and 
were enrolled into the study. Basic demographic and clinical data were collected. The 
headache questionnaire was read to participants and responses recorded. Then two 
researchers used the questionnaire information to independently classify each participant’s 
headache against the algorithm.  
1.3 Data Processing. Monthly Index of Medical Speciality (MIMS) searches were conducted 
on all medication with each classified into headache as a rare/uncommon or common/very 
common side effect. In every instance the highest rating of headache side effect of any of the 
drugs being taken by that participant was considered. 
1.4 Data Analysis. Descriptive statistics were used to report participants’ demographic, 
and clinical characteristics. The twelve-month prevalence rate for headache was calculated. A 
series of univariate logistic regressions were conducted to determine if age, gender, BMI, 
inpatient/outpatient status, length of mental illness or medication impacted on the likelihood 
of experiencing headache. Two researchers independently classified headaches. Responses 
were compared and inter-rater agreement assessed using a Kappa Measure of Agreement. 
Disagreements were discussed and consensus reached on classification. Overall prevalence 
rates for each headache type were calculated.  
Management of an individual’s headache was identified from the questionnaire and reviewed 
against the best practice management suggested for that person’s specific headache type.  
2.0 Results.  
We consecutively screened 148 people identified by their case manager as suitable and 48 
declined (Figure 1). One-hundred participants enrolled and completed the questionnaire. 
Table 1 lists participants’ demographic, clinical and medication details.  
The twelve-month prevalence of headache was 57% (57/100). No relationship was found 
between demographic variables and presence of headache, with no significant association 
between gender (OR 1.07, 95% CI 0.47-2.47, p=.87), age (OR 0.99, 95% CI 0.94-1.02, p=.25) 
and BMI (OR 1.02, 95% CI 0.96-1.08, p=.58) and presence of headache. We found no 
relationship between the measured psychiatric variables and presence of headache (Table 1) 
with no significant association between length of time from diagnosis of mental illness and 
presence of headache (OR 0.99, 95% CI 0.95-1.03, p=.61) nor inpatient/outpatient status (OR 
2.07, 95% CI 0.92-4.68 p=.08). Taking medication with headache as a common/very common 
side effect was not significantly related to headache status (OR 0.94, 95% CI 0.40-2.19, p=.89).  
The two raters demonstrated good agreement on headache classification agreeing on 47/58 
(weighted-κ=0.74, 95% CI 0.59-0.88). In all 67% (39/58) of reported headaches could be 
classified as distinct headache types against ICHD diagnostic criteria with 18/58 MH, 16/58 
TTH and 5/58 CGH. The prevalence of specific headache type was 17.8% (18/101) MH, 15.8% 
(16/101) TTH, 4.95% (5/101) CGH and 18.8% (19/101) OH. 
No participant with MH was prescribed migraine specific medication though 89% (n=16) were 
taking over-the-counter pain medication. The most commonly reported treatment for TTH was 
over-the-counter pain medication (75%, n=12). No-one with TTH received physical-therapy 
treatment such as manual therapy, exercise, education and postural correction for management 
of their headache. One participant with CGH received spinal manipulation only and none were 
provided with education, exercise or other active strategies. 
3.0 Discussion  
The aims of this study were to determine the prevalence, characteristics and management of 
headache in people with schizophrenia and schizoaffective disorder. Twelve-month prevalence 
of any headache was 57%, CGH 4.9%, MH 17.8%, TTH s 15.8% and OH 18.8%. The majority 
of MH (12/18) and TTH (12/16) sufferers treated themselves with over-the-counter 
paracetamol and/or sleep. No-one with TTH accessed physical-therapy services. One person 
with CGH received spinal manipulation but no active care. 
 
Our data support Lake9 who argued that most headaches in this population are not a result of 
psychosis, rather represent a comorbid physical illness9. We found no relationship between 
presence of headache and duration of mental illness nor participants’ inpatient/outpatient 
status. Furthermore, the majority of MH sufferers started experiencing MH prior to being 
diagnosed with mental illness. Prevalence rates of CGH and MH in this sample were 
comparable to the general population and TTH had lower prevalence10 further supporting the 
idea that headache is likely separate from the psychiatric condition.  
TTH (15.8%) was lower in prevalence than the general population (45%) as determined by Jull 
using the same questionnaire and a similar algorithm8.  It is hypothesised that TTH is the result 
of pain elicited by prolonged overloading on pericranial muscles combined with sensitisation 
of nociceptive pathways and abnormal pain processing in higher centres11,12. Prevalence and 
intensity of responses to nociception in clinical pain is diminished in people with schizophrenia 
attributed to abnormal processing of motivational-affective aspects of pain due to dysfunction 
in the Inferior Prefrontal Cortex and Amygdala 2. People with schizophrenia appear to have 
reduced response to prolonged nociception13. It is plausible that the sensitisation process of the 
TTH experience in the non-psychiatric population is blunted in people with 
schizophrenia/schizoaffective disorder contributing to lower prevalence.  Further investigation 
is needed to investigate this hypothesis as well as determine if physical impairments driving 
TTH are more severe in people with schizophrenia in order to provoke a response.  
Best-practice treatment for symptoms of acute MH include administration of simple analgesics, 
non-steroidal anti-inflammatory drugs and antiemetic medication14. Triptans or ergotamine 
should be instigated if these measures are not effective on three occasions. To be deemed 
effective treatment should provide at least 2 hours of relief15. The mean length duration of MH 
was 9.8hrs (SD 20.3hrs) suggesting that the majority of MH sufferers (12/18) were not 
receiving optimal care. No participant reported a neurologist review for headache nor being 
prescribed triptans or ergotamine. The WHO recommend symptomatic relief should include all 
symptoms, yet no-one reporting vomiting or nausea took antiemetic medication. In this survey 
11/18 people (61.1%) reported MH at least monthly and 7/18 (39%) at least twice per month 
suggesting their MH was insufficiently controlled and that prophylactic medication should 
have been implemented.  
 
Medication and sleep were the most common treatments adopted for TTH. Pharmacological 
treatment for TTH is complex and many variables impact on which medications are the most 
appropriate12. It was beyond the scope of this study to determine if participants took optimal 
medication for their TTH.  Neck and shoulder exercise reduce frequency and intensity of TTH 
and education on ergonomics and posture can reduce the load on myofascial tissues16,17. No-
one experiencing TTH reported receiving physiotherapy, exercise prescription or 
ergonomics/postural review, suggesting that treatment to address headache issues was 
suboptimal.  
A systematic review of randomised controlled trials determined a combination of cervical-
mobilisation, manipulation and cervico-scapular muscles  strengthening exercises is the most 
effective non-invasive management for CGH and should be the treatment of choice18. While 
one participant received cervical-manipulation it has been identified that manual 
therapy/manipulation without exercise prescription is a sub-standard treatment for CGH19.  
Physiotherapy must be more readily available and accessible to people in this population if 
they are to receive optimal treatment for headache. 
 
The sample size calculation by a biostatistician was based on a prevalence rate for any 
headache, however, it is acknowledged that a larger sample size would have provided richer 
data about individual headache types. Participants were recruited from only one facility and 
while their demographic data correlated to that found in a national survey of this population it 
may have impacted on results.  Recruiting community participants through the depot clinic 
may have impacted on the data. While participants were not limited to people on a Community 
Treatment Order it is unknown if the data would have been different if participants were 
recruited from all outpatient services.   
 
One potential confounder in the presence of headache is the use of the antipsychotic Olanzapine 
which has been associated with reduction of headache20. The impact of Olanzapine on presence 
of headache was not considered specifically in this study, however, 18.6% of people who did 
not experience headache were taking Olanzapine compared to 15.8% of people who did 
experience headache.  It is not possible to determine if those people taking Olanzapine were 
protected from headache. 
 The data from our survey suggests that headache is common in people with 
schizophrenia/schizoaffective disorder and mechanisms behind most headaches are likely not 
a direct result of their mental health condition. Overall management of headache in this 
population is very poor. Very few people were receiving adequate, evidence-based treatment 
for their headache. Employment of health professionals, such as physiotherapists, with skills 
in headache diagnosis and management within mental health services may address this 
problem.   
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